Eli Lilly’s Uncertain Triumph: A Trader’s Reflection
In the annals of a Reuters report, there emerged speculation that orforglipron, a nascent contender in the realm of obesity treatment, might find its way to the hallowed halls of the FDA’s approval before the year’s end. Though uncertainty lingers like a fog on a quiet morning, optimism permeated among those keeping watch over Eli Lilly’s fortunes.